New Delhi, February 12 Biocon announced on Thursday a more than five-fold increase in consolidated net profit to Rs 144 crore for the quarter ended December 2025, driven by gains in its generics and biosimilar business segments.
The Bengaluru-based company reported a net profit of Rs 25 crore for the same quarter of the previous fiscal year.
The company's revenue increased to Rs 4,173 crore for the period under review, compared to Rs 3,821 crore in the year-ago period, it stated in a press release.
The company's board has granted in-principle approval to acquire the remaining 2 per cent of Biocon Biologics Ltd's (BBL) paid-up equity share capital from employees of the group, on a fully diluted basis.
The consideration for acquiring these BBL shares from employees and other shareholders will be paid through a preferential allotment of equity shares, the company added.
"This quarter marks the culmination of several strategic steps that have created a stronger and simpler group structure," said Biocon Group Chairperson Kiran Mazumdar-Shaw.
The USD 1 billion raised cumulatively through two QIPs within an eight-month period demonstrates robust and sustained investor confidence in the company's overall business growth and direction, she added.
"The settlement of structured debt obligations earlier this year significantly strengthened our balance sheet, with an improvement in the consolidated debt-to-EBITDA ratio. This will improve profitability margins going forward, with the full impact of reduced interest costs of Rs 300 crore annually expected to be reflected in FY27," Mazumdar-Shaw stated.
Biocon shares closed 0.15 per cent down at Rs 375.25 per share on the BSE on Thursday.